Sims, Emily K.
Geyer, Susan M.
Long, S. Alice
Herold, Kevan C.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK061034, P30DK097512, R01DK057846, R01DK121929, R01DK129523, R01DK133881, U01 DK061010, U01 DK061042, U01 DK061058, U01 DK085453, U01 DK085461, U01 DK085465, U01 DK085466, U01 DK085476, U01 DK085499, U01 DK085504, U01 DK085509, U01 DK103153, U01 DK103180, U01 DK103266, U01 DK103282, U01 DK106984, U01 DK106994, U01 DK107013, U01 DK107014, U01DK127382, UC4 DK097835, UC4 DK106993)
John Templeton Foundation (62288)
Juvenile Diabetes Research Foundation International (SRA-2019-833-S-B)
Article History
Received: 22 March 2023
Accepted: 10 July 2023
First Online: 4 September 2023
Data availability
: Data are available upon reasonable request to the authors or via submission request via ExternalRef removed.
: The Type 1 Diabetes TrialNet Study Group is a clinical trials network funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Allergy and Infectious Diseases, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, through cooperative agreements U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01 DK085461, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085509, U01 DK103180, U01 DK103153, U01 DK085476, U01 DK103266, U01 DK103282, U01 DK106984, U01 DK106994, U01 DK107013, U01 DK107014, UC4 DK097835, and UC4 DK106993, and JDRF. EKS receives support from NIH grants R01DK121929, R01DK133881 and U01DK127382-012. EKS was also supported by the Doris Duke Charitable Foundation (grant 2021258) through the COVID-19 Fund to Retain Clinical Scientists collaborative grant programme, and by the John Templeton Foundation (grant 62288). The studies were supported by R01 DK057846 and R01 DK129523 from the NIH, and SRA-2019-833-S-B from JDRF (to KCH). This work utilised core services provided by the Diabetes Research Center grant P30 DK097512 (to Indiana University School of Medicine).
: EKS has received compensation for educational lectures on diabetes screening from Medscape and Health Matters CME. KCH has consulted for Provention Bio and is a co-inventor on a patent application for use of teplizumab for delay of stage 3 type 1 diabetes but without financial remuneration. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: EKS, SMG and KCH conceived the project, analysed data, obtained funding, and wrote and edited the manuscript. SAL analysed data and edited the manuscript. All authors approved the final version of the manuscript. KCH is responsible for the integrity of the work as a whole.
Free to read: This content has been made available to all.